Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus reinduction chemotherapy in pediatric refractory/relapsed ALL
ChiCTR2100049585Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2021
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bortezomib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Minimal residual disease (MRD), Overall survival and 1 more. Started Aug 2021; status: recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2100049585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049585.